WO2014140631A1 - Prx933 (prx-00933), un agoniste de 5ht2c, pour l'utilisation dans le traitement de l'hypertension - Google Patents

Prx933 (prx-00933), un agoniste de 5ht2c, pour l'utilisation dans le traitement de l'hypertension Download PDF

Info

Publication number
WO2014140631A1
WO2014140631A1 PCT/GB2014/050811 GB2014050811W WO2014140631A1 WO 2014140631 A1 WO2014140631 A1 WO 2014140631A1 GB 2014050811 W GB2014050811 W GB 2014050811W WO 2014140631 A1 WO2014140631 A1 WO 2014140631A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
treatment
prx933
hypertension
package
Prior art date
Application number
PCT/GB2014/050811
Other languages
English (en)
Inventor
Peter Richardson
Original Assignee
Proximagen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Limited filed Critical Proximagen Limited
Publication of WO2014140631A1 publication Critical patent/WO2014140631A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de PRX933 pour le traitement aigu de l'hypertension.
PCT/GB2014/050811 2013-03-15 2014-03-14 Prx933 (prx-00933), un agoniste de 5ht2c, pour l'utilisation dans le traitement de l'hypertension WO2014140631A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1304811.1 2013-03-15
GBGB1304811.1A GB201304811D0 (en) 2013-03-15 2013-03-15 Novel treatment for hypertension

Publications (1)

Publication Number Publication Date
WO2014140631A1 true WO2014140631A1 (fr) 2014-09-18

Family

ID=48226505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/050811 WO2014140631A1 (fr) 2013-03-15 2014-03-14 Prx933 (prx-00933), un agoniste de 5ht2c, pour l'utilisation dans le traitement de l'hypertension

Country Status (2)

Country Link
GB (1) GB201304811D0 (fr)
WO (1) WO2014140631A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057161A2 (fr) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation Composes de benzothieno[3,2-c]pyrazolyl et benzofurano[3,2-c]pyrazolyl, leur utilisation lors de maladies associees au recepteur 5-ht2c et leurs composes intermediaires
WO2004000829A1 (fr) * 2002-06-19 2003-12-31 Biovitrum Ab Nouveau procede

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057161A2 (fr) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation Composes de benzothieno[3,2-c]pyrazolyl et benzofurano[3,2-c]pyrazolyl, leur utilisation lors de maladies associees au recepteur 5-ht2c et leurs composes intermediaires
WO2004000829A1 (fr) * 2002-06-19 2003-12-31 Biovitrum Ab Nouveau procede

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BJÖRN M. NILSSON: "5-Hydroxytryptamine 2C (5-HT 2C ) Receptor Agonists as Potential Antiobesity Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 14, 1 July 2006 (2006-07-01), pages 4023 - 4034, XP055010147, ISSN: 0022-2623, DOI: 10.1021/jm058240i *
HOPKINS COREY R: "ACS Chemical Neuroscience Molecule Spotlight on Lorcaserin", ACS CHEMICAL NEUROSCIENCE, vol. 1, no. 11, November 2010 (2010-11-01), pages 718 - 719, XP002723680, ISSN: 1948-7193 *
MCMURRAY GORDON ET AL: "The 5-HT2C receptor agonists Ro-60-0175 and CP-809101 increase voided volume in conscious spontaneously hypertensive rats", ACTA PHARMACOLOGICA SINICA, vol. 27, no. suppl. 1, 1 July 2006 (2006-07-01), NATURE PUBLISHING GROUP, US, CN, pages 438, XP009177718, ISSN: 1671-4083 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation

Also Published As

Publication number Publication date
GB201304811D0 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
TWI472327B (zh) Ｓ１ｐ受體激動劑劑量療法
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
AU2006247526A1 (en) Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
KR101984500B1 (ko) 날트렉손 요법에서 약물 생체이용률의 증가
CN107050455A (zh) 用于治疗中枢介导的恶心及呕吐的组合物及方法
KR20160095076A (ko) 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법
WO1995017889A1 (fr) Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle
TW200534852A (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
MX2010011400A (es) Uso de dronedarona o una sal farmaceuticamente aceptable de lo mismo, para la preparacion de un medicamento para regular el nivel de potasio en la sangre.
JP2005533830A (ja) トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ
JP2011518872A (ja) 不整脈およびクレアチニン濃度の上昇を有する患者を治療する薬剤を調製するための単独または組み合わせでのドロネダロンの使用
US6949548B2 (en) Combination therapy for the treatment of heart failure
WO2014140631A1 (fr) Prx933 (prx-00933), un agoniste de 5ht2c, pour l'utilisation dans le traitement de l'hypertension
JP2002535367A5 (fr)
Erdmann The management of heart failure–an overview
WO2009143662A1 (fr) Composition pharmaceutique comprenant un agent bloquant du canal de calcium et des vitamines de la famille b et utilisation de celle-ci
ZA200409200B (en) Combination of angiotensin II receptor blocker and betablocker for secondary prevention of myocardial infarction
Wing et al. Candesartan and hydrochlorothiazide in isolated systolic hypertension
WO2011027021A1 (fr) Procédé de traitement de l'hypertension
JP4733348B2 (ja) 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤
Abcha et al. Actual place of diuretics in hypertension treatment
RU2530628C1 (ru) Фармацевтическая композиция и набор для лечения и/или предупреждения нарушений, связанных с ожирением, и способ лечения и/или предупреждения нарушений, связанных с ожирением
WO2015001357A2 (fr) Association de médicaments et son utilisation en thérapie
PROFILE RENEDlL
Chrysant et al. SAFETY AND TOLERABILITY OF COMBINATION OLMESARTAN MEDOXOMIL (OM)+ AMLODIPINE BESYLATE (AML)+ HYDROCHLOROTHIAZIDE (HCTZ) IN PATIENTS WITH HYPERTENSION: THE TRINITY STUDY: PP. 5.166

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14711590

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14711590

Country of ref document: EP

Kind code of ref document: A1